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GUT MICROBIOTA CHANGE AND TIME OF RESTORE IN INTENSIVE CARE
THERAPY: A CASE REPORT
Francesca Borgo1, Elisa Borghi1, Silvia Marzorati3, Gaetano Iapichino2,3, Giulia Morace1
ABSTRACT
Exposure of gut microbiota to antibiotics can promote antibiotic resistance
and development of diseases caused by multi-drug-resistant organisms.
Here we present a case of a 54-year-old male patient with a diagnosis of
acute cholecystitis with significant biliary duct leakage, admitted to Intensive
Care Unit (ICU) due to a septic syndrome after surgery. Fecal microbial
population was analyzed by DGGE and Real Time PCR during and after a
combined antibiotic therapy and enteral nutritional feeding. Gut microbiota
dysbiosis was demonstrated during ICU recovery. After antibiotic therapy
discontinuation and the switch to normal diet, microbial gut population
gradually increased up to values comparable with those of a healthy subject.
Bifidobacterium spp. took longer to re-stabilize, reaching normal value after
two weeks. Our case report corroborates the resilient nature of gut
microbiota, but points out the long time needed to recover after antibiotic
treatment, paving the way to supplementation with key probiotic species.
Keywords: Gut Microbiota, Intensive Care Unit, Antibiotic therapy,
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INTRODUCTION
Exposure of gut microbiota to antibiotics selects for multi-
drug-resistant organisms, which can be a major clinical
problem. Antimicrobial treatment not only target
pathogenic bacteria, but also can have damaging effects
on the ecology of commensal species [1]. The longer is
the exposure to drugs, such as in critically ill patients, the
deeper is the impact on microbial ecology, eventually
leading to a complete ecological collapse. The selective
pressures imposed by modern intensive care therapy,
including multiple antibiotic exposure, provision of all
nutrients exclusively through intravenous route (total
parenteral nutrition) is the main driving force of microbial
changes. However, the gut microbiota seems to be
relatively resilient to antibiotic challenge, and after short-
term modification returns to its pre-treatment composition
[2]. A better understanding of the ecological perturbations
that characterize the microbiota during prolonged
intensive care therapy, in terms of both composition and
restoration time, is crucial to develop new supportive
strategies in intensive care patients. Here we
characterized the biodiversity and composition of gut
microbial communities (bacterial and fungal) in a patient
hospitalized in intensive care unit.
CASE REPORT
A 54 years old male patient with no previous medical
history was admitted in September 2014 to the
Emergency Department of San Paolo Hospital in Milan
with a diagnosis of acute cholecystitis with significant
biliary duct leakage. The same day, he underwent urgent
surgery and was admitted at the Intensive Care Unit
(ICU) due to a septic syndrome. SOFA and SAPS
score were 9 and 37, respectively, with a predicted
mortality risk of 18%.
During ICU stay, the patient underwent several surgical
and non-surgical procedures: nasobiliary and
transhepathic percutaneous drainage (PTBD);
endoscopic retrograde cholangiopancreatography
(ERCP) and biliary duct endoprothesis positioning; open
abdomen treatment in severe compartment syndrome.
ICU hospitalization lasted 51 days. The patient suffered
of a septic shock with a hemodynamic instability that
required invasive monitoring and vasopressors,
leucopenia (WBC 2300), high procalcitonin levels (PCT).
At day 8, blood and bile culture gave back Escherichia
coli and E. coli/ Klebsiella pneumoniae, respectively. A
combined antibiotic therapy was started (Table 1).
Table 1 Antibiotic therapy
Antibiotic
therapy
Dosage Administra
tion route
Period
(from day-
to day)
Cefazolin 6 g/die iv* 1-4
Metronidazole 2 g/die iv 1-6
Fluconazole 200 mg/die ngt§ 3-17
Cefotaxime 12 g/die iv 4-8
Gentamicin 560 mg/die iv 5-12
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Meropenem 4 g/die iv 12-17
Colistin 4000000 UI ngt 13-18
* intravenous administration, § nasogastric tube
Fig1. Fecal Gut Microbiota Ecology. A The UPGMA
dendrogram obtained for the DGGE analysis; B
Quantification of microrganisms detected in fecal
samples using real time PCR. Results are expressed in
Log10 of genome number/ g stool.
At day 9, K. pneumoniae was also isolated from blood
culture and E.coli in bronchial tube. At day 11, bile culture
was positive for Proteus spp., E. coli, Enterococcus
faecium and E. faecalis. At day 20, a progressive
resolution and recovery of organs function were
observed, together with respiratory weaning till
spontaneous breathing. The antibiotic therapy was then
discontinued. Nutritional support has been guaranteed
via enteral feeding (Nutrison ST: 500 kcal 1st day, 1000
kcal 2nd day; Prosure (Abbot) 1500 Kcal/day).
Spontaneous oral feeding started at day 40, with a
consequent reduction in enteral nutritional support.
No feces were passed until day 8; from day 8 till 13
diarrhea developed (1000-2500 ml/die), then fecal transit
normalized (200-300 ml/die).
Fecal samples were collected and immediately stored at
– 80° C until analysis, at days 9, 11, 14, 16, 32, 35, 38
and at day 88, after strong amelioration of patient’s
clinical conditions and admission to the Internal Medicine
ward. Total bacterial DNA extractions were performed
with 200 mg fecal material using the Spin stool DNA kit
(Stratec Molecular, Berlin, Germany), according to the
manufacturer’s instructions. PCR amplifications of total
bacterial DNA were obtained using the primer pair HDA1-
GC and HDA2, and the thermocycling program as
described previously [4]. The Denaturing Gradient Gel
Electrophoresis (DGGE) analysis was performed with a
Dgene System (Bio-Rad Hercules) using a 0.8 mm 8%
polyacrylamide gel with 35–60% gradient of urea and
formamide, as reported previously [5]. Calculation of
similarity in the profiles of bands was based on Dice
correlation coefficient (Figure 1). Dendrogram was
obtained by means of the Un- weighted Pair Group
Method using Arithmetic Average (UPGMA) clustering
algorithm.
Presence and quantification of the most representative
species and microbial groups (referred as core
microbiota) was carried out by Real-time PCR
quantification (qPCR, Figure 2). qPCR was carried out
using the StepOne instrument (Applied Biosystems), the
SYBR® Green chemistry (ThermoScientific, USA).
Standard curves were obtained for each qPCR run using
serial dilutions of control DNA. The specific 16S rRNA
primers and qPCR conditions used for
Bacteroides/Prevotella group, Bifidobacterium spp. And
Enterobacteriaceae group are reported by Bartosch and
colleagues [6]; for Lactobacillus spp. We used the
conditions designed by Delroisse et al. [7].
DISCUSSION
In this case report, we monitored patient’s gut microbiota
during ICU hospitalization and eventually at his recovery
from critical conditions. Different reports are available on
the effects of artificial nutrition and antibiotic treatment on
gut microbial diversity. Artificial nutrition promotes the
reduction of fecal volume and gut microbiota dysbiosis
that eventually could be implicated in a leaky gut
condition [8]. The dysbiosis is worsened by antibiotics
administration, and could selects resistant
microorganisms that overgrowth and colonize the
gastrointestinal tract of patients. Prolonged and broad-
spectrum therapies are associated to deeper changes in
the microbial
ecology [6].
Due to the critical conditions of the patient, we used
several combinations of antimicrobial therapies, driven by
isolation of different pathogens during the ICU staying. As
expected, deep changes in the microbial ecology
accompanied the use of supportive nutrition and
antibiotics.
DGGE profiles of all collected samples set up two main
clusters (46% similarity by Dice correlation index): one
represented by samples at days 14 and 16 (77% of
similarity), the other cluster included 2 sub-clusters (65%
similarity), days 9 and 11, and days 32, 35, 38 and 88
(Figure 1A).
The previous patient history did not report any
inflammatory gut disease. Day 9 sample could be
representative of the initial situation, being the first stool
that has been passed since hospital admission. Although
a diarrhea condition developed, we observed the most
dramatic change after 14 days of antibiotic treatment.
Day 14 and 16 samples showed the lower degree in
microbial biodiversity and corresponded to the
simultaneous Fluconazole, Meropenem, Colistin
treatment (Table 1).
It is interesting to note that samples from days 32, 35 and
38 clustered at 80% of similarity. These samples where
obtained during patient’s ICU staying after antibiotics
discontinuation and normal feeding initiation. The last
sample, collected during the patient convalescence in
Internal Medicine ward (day 88, without antibiotic
treatment and normal alimentation), presented a DGGE
profile with a 65% of similarity with days 32, 35 and 38.
We confirmed DGGE results by absolute quantification of
the most representative bacterial groups (Figure 1B).
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Despite day 9 was the first stool the patient has passed
since hospital admission, quantification of bacterial
species and genera showed a higher abundance of
Enterococcus spp. and Enterobacteriaceae compared
with healthy population [9]. The antibiotic treatment
started at the admission in ICU ward, thus it could have
influenced the overgrowth of these species, according to
literature data [7]. E. faecalis, a species with high
antibiotic resistance traits, as well as E.coli and P.
mirabilis ESBL (extended spectrum beta-lactamase)-
producing were cultured form bile at day 11. We cannot
exclude their translocation from gut.
From day 11 till day 16 we observe a dramatic decrease
in Bifidobacterium spp., Lactobacillus spp., Bacteroides
spp. ; then, these core microbiota genera started to
gradually regrow from day 32 to day 88, 16 days after
antimicrobial therapy discontinuation.
The abundance in Enterococcus spp. and
Enterobacteriaceae remained above normal until the
patient’s discharge from ICU: the decrease in their gut
content concurred with normalization of other gut
commensals.
Bifidobacterium spp. took longer to stabilize, starting to
regrow at day 35, and reaching a normal abundance at
day 38. This genus might exert an inhibitory activity
against Enterobacteriaceae and Enterococcus spp., by
producing acetate and lowering the intestinal pH [10].
CONCLUSION
The case report here presented shows that short period
of antimicrobial therapy could trigger a remarkable
dysbiosis, in terms of both biodiversity and
concentrations. However, the gut microbiota is a resilient
entity with a species-specific recovery time. The delay in
the regrow of some species, i.e. Bifidobacterium spp.,
could promote transient colonization with potentially
pathogenic species that can overgrow and eventually
translocate causing systemic infection.
Probiotic administration of key species during
antimicrobial therapy could thus favor the reduction of
dysbiosis and promote a more rapid return to a healthy
microbial community
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